Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

[11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy.

Passamonti L, Rodríguez PV, Hong YT, Allinson KSJ, Bevan-Jones WR, Williamson D, Jones PS, Arnold R, Borchert RJ, Surendranathan A, Mak E, Su L, Fryer TD, Aigbirhio FI, O'Brien JT, Rowe JB.

Neurology. 2018 May 29;90(22):e1989-e1996. doi: 10.1212/WNL.0000000000005610. Epub 2018 Apr 27.

2.

Neuroinflammatory and morphological changes in late-life depression: the NIMROD study.

Su L, Faluyi YO, Hong YT, Fryer TD, Mak E, Gabel S, Hayes L, Soteriades S, Williams GB, Arnold R, Passamonti L, Rodríguez PV, Surendranathan A, Bevan-Jones RW, Coles J, Aigbirhio F, Rowe JB, O'Brien JT.

Br J Psychiatry. 2016 Dec;209(6):525-526. Epub 2016 Oct 6.

3.

Atomoxetine restores the response inhibition network in Parkinson's disease.

Rae CL, Nombela C, Rodríguez PV, Ye Z, Hughes LE, Jones PS, Ham T, Rittman T, Coyle-Gilchrist I, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB.

Brain. 2016 Aug;139(Pt 8):2235-48. doi: 10.1093/brain/aww138. Epub 2016 Jun 24.

4.

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.

Borchert RJ, Rittman T, Passamonti L, Ye Z, Sami S, Jones SP, Nombela C, Rodríguez PV, Vatansever D, Rae CL, Hughes LE, Robbins TW, Rowe JB.

Neuropsychopharmacology. 2016 Jul;41(8):2188. doi: 10.1038/npp.2016.46. No abstract available.

5.

Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.

Ye Z, Rae CL, Nombela C, Ham T, Rittman T, Jones PS, Rodríguez PV, Coyle-Gilchrist I, Regenthal R, Altena E, Housden CR, Maxwell H, Sahakian BJ, Barker RA, Robbins TW, Rowe JB.

Hum Brain Mapp. 2016 Mar;37(3):1026-37. doi: 10.1002/hbm.23087. Epub 2016 Jan 12.

Supplemental Content

Loading ...
Support Center